Laurel Wealth Advisors (California)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$434K	Sell	5,226 -2,000	-28%	-$162K	0.04%	393
2022 Q3	$573K	Sell	7,226 -57	-0.8%	-$4.8K	0.06%	315
2022 Q2	$541K	Sell	7,283 -1,710	-19%	-$128K	0.06%	337
2022 Q1	$808K	Sell	8,993 -6,285	-41%	-$580K	0.07%	290
2021 Q4	$1.71M	Sell	15,278 -155	-1%	-$18.7K	0.13%	156
2021 Q3	$1.94M	Sell	15,433 -1,108	-7%	-$143K	0.36%	55
2021 Q2	$2.24M	Sell	16,541 -722	-4%	-$94.9K	0.29%	86
2021 Q1	$2.34M	Sell	17,263 -1,413	-8%	-$212K	0.35%	64
2020 Q4	$2.63M	Buy	18,676 +396	+2%	+$50.7K	0.39%	60
2020 Q3	$2.04M	Buy	18,280 +1,051	+6%	+$118K	0.34%	64
2020 Q2	$1.93M	Buy	17,229 +11	+0.1%	+$1.08K	0.35%	71
2020 Q1	$1.33M	Buy	17,218 +3,850	+29%	+$341K	0.31%	82
2019 Q4	$1.27M	Sell	13,368 -1,000	-7%	-$86.5K	0.21%	130
2019 Q3	$1.1M	Hold	14,368	–	–	0.19%	137
2019 Q2	$1.26M	Sell	14,368 -574	-4%	-$49K	0.28%	100
2019 Q1	$1.35M	Sell	14,942 -1,711	-10%	-$146K	0.33%	84
2018 Q4	$1.19M	Sell	16,653 -77	-0.5%	-$6.2K	0.35%	79
2018 Q3	$1.6M	Sell	16,730 -1,380	-8%	-$134K	0.39%	65
2018 Q2	$1.72M	Sell	18,110 -277	-2%	-$25.5K	0.46%	54
2018 Q1	$1.61M	Hold	18,387	–	–	0.5%	53
2017 Q4	$1.56M	Sell	18,387 -4,160	-18%	-$348K	0.45%	62
2017 Q3	$1.95M	Buy	22,547 +7,022	+45%	+$563K	0.65%	36
2017 Q2	$1.2M	Buy	+15,525	New	+$1.1M	0.43%	73

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Laurel Wealth Advisors (California)'s XBI Position: Q4 2022 in Review

Laurel Wealth Advisors (California) reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 28% in Q4 2022, selling an estimated $162K and leaving 5,226 shares worth $434K. The position accounts for 0.04% of the portfolio, ranked #393.

Laurel Wealth Advisors (California) first reported a position in XBI in Q2 2017 and has held it in 23 quarters since. The position peaked at $2.63M in Q4 2020. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Laurel Wealth Advisors (California) held 5,226 shares of State Street SPDR S&P Biotech ETF worth $434K as of Q4 2022.
Laurel Wealth Advisors (California) sold 2,000 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $162K.
State Street SPDR S&P Biotech ETF made up 0.04% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #393 holding.
Laurel Wealth Advisors (California) first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 23 quarters since.
Laurel Wealth Advisors (California)'s State Street SPDR S&P Biotech ETF position peaked at $2.63M in Q4 2020.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.